Search results for "PORIN"

showing 10 items of 260 documents

Effectiveness of substituting cyclosporin A with tacrolimus in reducing gingival overgrowth in renal transplant patients

2009

Objectives: this study aims to evaluate the effectiveness of periodontal therapy combined with tacrolimus in the suppression of gingival overgrowth (GO) and the effect on GO of changing from cyclosporin A to tacrolimus. Patients and methods: sixteen renal transplant patients, averaging 52 years of age, whose kidney function was stable and were receiving treatment with cyclosporin A, were randomly assigned to one of two groups. In the experimental group, patients were instructed in oral hygiene and underwent periodontal treatment, whereas in the control group, only oral hygiene instructions were given. After the first visit and the change of medication from cyclosporine to tacrolimus in both…

ImmunosupressióMalalties de les genivesTrasplantament renalTherapeutic useImmunosupressive agentsMalalties periodontalsTherapeuticsTerapèuticaCiclosperinaGum diseasesKidney transplantationsurgical procedures operativeEfectes secundaris dels medicamentsÚs terapèuticCyclosporineDrug side effectsImmunosupressorsPeriodontal diseaseUNESCO:CIENCIAS MÉDICASImmunosuppression
researchProduct

In situ kinetic modelling of intestinal efflux in rats: functional characterization of segmental differences and correlation with in vitro results.

2007

The objective was to devise and apply a novel modelling approach to combine segmental in situ rat perfusion data and in vitro cell culture data, in order to elucidate the contribution of efflux in drug absorption kinetics. The fluoroquinolone CNV97100 was used as a model P-gp substrate. In situ intestinal perfusion was performed in rat duodenum, jejunum, ileum and colon to measure the influence of P-gp expression on efflux. Inhibition studies of CNV97100 were performed in the presence of verapamil, quinidine, cyclosporin A and p-aminohippuric acid. Absorption/efflux parameters were modelled simultaneously, using data from both in situ studies as well as in vitro studies. The maximal efflux …

In situAbsorption (pharmacology)MaleColonVasodilator AgentsPharmaceutical ScienceIleumMuscarinic AntagonistsModels BiologicalIntestinal absorptionPermeabilityJejunumCiprofloxacinCyclosporin aIntestine SmallmedicineAnimalsPharmacology (medical)ATP Binding Cassette Transporter Subfamily B Member 1Intestinal MucosaRats WistarP-glycoproteinPharmacologybiologyDose-Response Relationship DrugMolecular StructureChemistryGeneral MedicineQuinidineRatsKineticsmedicine.anatomical_structureBiochemistryIntestinal AbsorptionVerapamilbiology.proteinBiophysicsCyclosporinep-Aminohippuric AcidEffluxAlgorithmsImmunosuppressive AgentsFluoroquinolonesBiopharmaceuticsdrug disposition
researchProduct

Human interleukin 2: molecular biology, physiology and clinical possibilities.

1986

Interleukin 2Antigens Differentiation T-Lymphocytemedicine.medical_treatmentT-LymphocytesImmunologyPhysiologyGraft vs Host DiseaseCyclosporinsBiologyInterleukine 2MiceNeoplasmsmedicineImmune ToleranceImmunology and AllergyAnimalsHumansReceptors ImmunologicBone Marrow TransplantationMacrophagesLymphokineImmunization PassiveAntibodies MonoclonalImmunosuppressionReceptors Interleukin-2HematologyImmunotherapyRecombinant ProteinsKiller Cells NaturalImmunologyAntigens SurfaceInterleukin-2medicine.drugImmunobiology
researchProduct

Growth, interleukin-2 production, and responsiveness to IL-2 in T4- positive T Lymphocyte populations from malignant cutaneous T cell lymphoma (Sezar…

1984

Abstract Functional analysis and surface phenotyping using monoclonal antibodies have revealed that malignant T lymphocyte populations in the peripheral blood of patients with Sezary's syndrome resemble the T helper cell populations from normal individuals. In this article we have studied the effects of the immunosuppressive drug cyclosporine A (CsA) on growth, interleukin-2 (IL-2) production, and the induction of IL-2 responsiveness of peripheral blood monocytes (PBMs) from five patients with Sezary's syndrome in vitro, using the lectin phytohemagglutinin (PHA) and the phorbol ester phorbol myristate acetate (PMA) as stimuli. The following results were obtained: PHA-induced cell proliferat…

Interleukin 2medicine.medical_specialtyT cellImmunologyCyclosporinsBiologyLymphocyte ActivationBiochemistryCyclosporin aInternal medicinemedicineHumansSezary SyndromePhytohemagglutininsReceptorCell growthCutaneous T-cell lymphomaT-Lymphocytes Helper-InducerCell BiologyHematologyT helper cellT lymphocytemedicine.diseasePhenotypemedicine.anatomical_structureEndocrinologyInterleukin-2Tetradecanoylphorbol Acetatemedicine.drugBlood
researchProduct

Aquaporin 3 Expression Loss in Urothelial Carcinoma: Association with Tumor Invasion Depth, but not with Grading?

2017

We have previously provided molecular evidence of expression of aquaporin 3 (AQP3) in normal human urothelium and in UBC of various stages. Whereas former studies demonstrated that loss of AQP3 was associated with invasive and high-grade disease and worse progression-free and cancer-specific survival, this report investigates the expression of AQP3 in associated CIS. Contrary to what we had expected, all CIS specimens were shown to exhibit strong AQP3 expression, suggesting loss of AQP3 in UBC is primarily associated with the ability of tumor cells for invasion but not with grading as sign of dedifferentiation.

Invasion depthPathologymedicine.medical_specialtyUrologyCarcinoma in situShort CommunicationBladder030232 urology & nephrologycarcinoma in situMolecular evidenceBiologymedicine.disease03 medical and health sciences0302 clinical medicineOncologyAquaporin 3030220 oncology & carcinogenesisimmunohistochemistrymedicineImmunohistochemistryUrotheliumaquaporin 3Grading (tumors)urothelial carcinomaUrothelial carcinomaBladder Cancer (Amsterdam, Netherlands)
researchProduct

The Influence of Adalimumab and Cyclosporine A on the Expression Profile of the Genes Related to TGFβ Signaling Pathways in Keratinocyte Cells Treate…

2020

Background. In the treatment of moderate to severe psoriasis, cyclosporine A (CsA) conventional therapy is used and biological, anti-cytokine treatment using, for example, anti-TNF drug—adalimumab. Aim. This study aimed at investigating the effect of CsA and adalimumab on the profile of mRNAs and protein expression associated with transforming growth factor β (TGFβ) pathways in human keratinocyte (HaCaT) culture previously exposed to lipopolysaccharide (LPS). Materials and Methods. HaCaT culture was exposed to 1 ng/ml LPS for 8 hours+8 μg/ml adalimumab for 2, 8, and 24 hours or 1 ng/ml LPS for 8 hours+100 ng/ml CsA for 2, 8, and 24 hours and compared to the control culture. Sulphorodamine B…

KeratinocytesLipopolysaccharidesArticle SubjectLipopolysaccharideMicroarrayImmunologyPharmacologychemistry.chemical_compoundTransforming Growth Factor betaCell Line TumorCyclosporin aPathologymedicineRB1-214Humansskin and connective tissue diseasesCytotoxicityRhodaminesAdalimumabCell BiologyBone morphogenetic protein 6HaCaTmedicine.anatomical_structurechemistryCyclosporineKeratinocyteResearch ArticleSignal TransductionTransforming growth factorMediators of Inflammation
researchProduct

[Apoptosis of human leukemic cells induced by topoisomerase I and II inhibitors].

1996

International audience; Comparison between five human leukemic lines (BV173, HL60, U937, K562, KCL22) suggest that the main determinant of their sensitivity to topoisomerase I (camptothecin) and II (VP-16) inhibitors is their ability to regulate cell cycle progression in response to specific DNA damage, then to die through apoptosis: the more the cells inhibit cell cycle progression, the less sensitive they are. The final pathway of apoptosis induction involves a cytoplasmic signal, active at neutral pH, needing magnesium, sensitive to various protease inhibitors and activated directly by staurosporine. Modulators of intracellular signaling (calcium chelators, calmodulin inhibitors, PKC mod…

Leukemia[SDV]Life Sciences [q-bio]Cell CycleApoptosisCell DifferentiationDNA Neoplasm[SDV.BC]Life Sciences [q-bio]/Cellular BiologyStaurosporine[SDV] Life Sciences [q-bio]AlkaloidsDNA Topoisomerases Type IIDNA Topoisomerases Type ITumor Cells CulturedHumansTopoisomerase II InhibitorsCamptothecinTopoisomerase I Inhibitors[SDV.BC] Life Sciences [q-bio]/Cellular BiologyProtein Kinase CEtoposideSignal Transduction
researchProduct

Pharmacogenetic Study of ABCB1 and CYP3A5 Genes During the First Year Following Heart Transplantation Regarding Tacrolimus or Cyclosporine Levels

2011

Pharmacogenetics explains part of the interindividual variability in drug responses. Many published works about the effects of single nucleotide polymorphisms (SNPs) on immunosuppressive drug blood levels present contradictory results. We evaluated the SNPs in ABCB1 (glycoprotein P) and CYP3A5 (metabolic enzyme) genes, seeking correlate them with tacrolimus or cyclosporine levels during the first year after heart transplantation. One blood sample was obtained from each of 41 patients: 26 treated with cyclosporine and 15 with tacrolimus. We characterize the SNPs rs1045642, 1128503, 2032582, 2235013, 2235033, 2229109, 3213619, 9282564 in ABCB1 and rs10264272, 776746 in CYP3A5 genes using the …

Linkage disequilibriummedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BGenotypemedicine.medical_treatmentSingle-nucleotide polymorphismBiologyPharmacologyPolymorphism Single NucleotideGastroenterologyLinkage DisequilibriumTacrolimusGene FrequencyInternal medicineGenotypemedicineCytochrome P-450 CYP3AHumansDrug Dosage CalculationsATP Binding Cassette Transporter Subfamily B Member 1CYP3A5Heart transplantationTransplantationTacrolimusPhenotypeImmunosuppressive drugPharmacogeneticsSpainCyclosporineHeart TransplantationSurgeryDrug MonitoringImmunosuppressive AgentsPharmacogeneticsTransplantation Proceedings
researchProduct

Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro.

2009

Inhibition of the mutated fms-like tyrosine kinase 3 (FLT3) receptor tyrosine kinase is a promising therapeutic strategy in acute myeloid leukaemia (AML). However, development of resistance to FLT3 tyrosine kinase inhibitors (TKI), such as PKC412A, has been described recently. This observation may have an increasing impact on the duration of response and relapse rates in upcoming clinical trials employing FLT3-TKI. Herein we investigated two representatives of a novel class of FLT3-TKI: Bis(1H-indol-2-yl)methanones. Both compounds effectively induced apoptosis in FLT3-internal tandem duplicate (ITD)-transfected murine myeloid cells and in primary FLT3-ITD positive blasts. Combination of bot…

MAPK/ERK pathwayIndolesmedicine.drug_classAntineoplastic AgentsApoptosisTransfectionTyrosine-kinase inhibitorReceptor tyrosine kinaseCell Linefluids and secretionshemic and lymphatic diseasesmedicineTumor Cells CulturedHumansProtein kinase Bbiologyhemic and immune systemsHematologyStaurosporineIn vitroLeukemia Myeloid Acutefms-Like Tyrosine Kinase 3Drug Resistance NeoplasmTandem Repeat SequencesTrk receptorembryonic structuresFms-Like Tyrosine Kinase 3Cancer researchbiology.proteinTyrosine kinasepsychological phenomena and processesBritish journal of haematology
researchProduct

Sodium butyrate with UCN-01 has marked antitumour activity against cervical cancer cells.

2010

The effect of combining sodium butyrate (NaB), a histone deacetylase inhibitor, and 7-hydroxy-staurosporine (UCN-01) on cytotoxicity in human cervical carcinoma cells was evaluated.HeLa and CaSki cells were treated using NaB alone or in combination with staurosporine (STS) or its analog UCN-01. Cytotoxicity was determined by flow cytometry and morphological assays. Apoptotic pathways were characterized by Western blotting and immunostaining. CaSki cells were also xenografted into nude mice to assess the in vivo effects of NaB/UCN-01 combination.Treatment with NaB and STS or UCN-01 resulted in enhanced apoptosis of cancer cells. Apoptosis involved mitochondrial pathways and overexpression of…

MESH : StaurosporineMESH : Hela CellsMESH : Antineoplastic Combined Chemotherapy Protocolshealth care facilities manpower and servicesUterine Cervical NeoplasmsMESH: ButyratesMESH: Cell CycleApoptosisMESH: Papillomavirus Infections[ SDV.CAN ] Life Sciences [q-bio]/CancerMiceAntineoplastic Combined Chemotherapy ProtocolsMESH: AnimalsMESH: Human papillomavirus 18MESH : Human papillomavirus 18MESH : Femalehealth care economics and organizationsMESH: Human papillomavirus 16MESH : Papillomavirus InfectionsHuman papillomavirus 16Human papillomavirus 18Cell CycleMESH : Mice NudeMESH: Uterine Cervical NeoplasmsMESH: Antineoplastic Combined Chemotherapy ProtocolsButyratesMESH: Cell Growth ProcessesFemaleMESH: Xenograft Model Antitumor Assaysendocrine systemMESH: Cell Line TumoreducationMESH : Uterine Cervical NeoplasmsMice Nude[SDV.CAN]Life Sciences [q-bio]/CancerCell Growth ProcessesMESH : Xenograft Model Antitumor Assays[SDV.CAN] Life Sciences [q-bio]/CancerCell Line TumorMESH : ButyratesMESH : MiceMESH : Cell CycleMESH: Mice Nudeotorhinolaryngologic diseasesAnimalsHumansMESH: MiceMESH: HumansMESH : Cell Line TumorMESH: ApoptosisPapillomavirus InfectionsMESH : HumansMESH : Human papillomavirus 16StaurosporineXenograft Model Antitumor AssaysMESH: Hela CellsMESH : Cell Growth ProcessesMESH: StaurosporineMESH : AnimalsMESH: FemaleMESH : ApoptosisHeLa Cells
researchProduct